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ABSTRACT 
Background    Procalcitonin (PCT) is a known diagnos-
tic marker of bacterial infection. There are no previous 
reports of PCT concerning acute liver failure (ALF). We 
evaluated the clinical value of serum PCT levels in pa-
tients with ALF.
Methods    Forty-four patients with acute hepatitis (19 
men and 25 women; median age, 40 years; range, 20–79 
years) were retrospectively enrolled from January 2001 
and June 2015. PCT levels were measured by saved 
serum samples obtained within 3 days after admission. 
ALF was defined as prothrombin time (PT) < 40% re-
gardless of hepatic encephalopathy.
Results    Serum PCT levels were significantly higher in 
the patients with ALF (n = 16) than in those with non-
ALF (n = 28) [0.25 (0.13–2.66) ng/mL vs. 0.165 (0.03–
1.08), P = 0.00967]. Creatinine, total bilirubin, and 
direct bilirubin were positively correlated, and PT was 
negatively correlated with PCT. Receiver operating char-
acteristic curve analysis showed an area under the curve 
of 0.74 for detecting ALF. With a PCT cut-off value of 
0.5 ng/mL, the presence of ALF could be demonstrated 
with low sensitivity (37.5%) and high specificity (96.5%) 
with high positive (85.7%) and negative (72.9%) predic-
tive value. Multivariate analysis showed that PCT was 
an independent factor associated with the presence of 
ALF. The cumulative survival rate was also significantly 
lower in patients with PCT ≥ 0.5 ng/mL (P = 0.0314), but 
it was not an independent prognostic factor.
Conclusion    Serum PCT level was significantly higher 
in patients with ALF.
Key words    acute hepatitis; acute liver failure; fulmi-
nant hepatitis; procalcitonin
Acute liver failure (ALF), especially fulminant hepatitis 
is a severe liver disorder with high mortality.1 Despite 
advances in intensive care, the mortality rate remains 
high.2 Liver transplantation (LT) is regarded as the stan-
dard therapy for patients with ALF, and the cumulative 
survival rates at 1, 5, and 10 years after LT in Japan were 
79%, 74%, and 73%, respectively.3 For early prediction 
of disease severity, it is critically important for patients 
to receive LT. Scoring systems using multiple factors [age; 
duration from onset to hepatic encephalopathy; creati-
nine (Cre), bilirubin, and cholinesterase levels; platelet 
counts; prothrombin time (PT); arterial blood pH; and 
liver atrophy] have been reported to be useful for pre-
dicting the severity and prognosis of ALF.4–9 Moreover, 
factor V levels, interleukin-10, tumor necrosis factor-α, 
serum Gc-globulin, and M30 have also been identified 
to predict the prognosis of ALF as single prognostic fac-
tors.10–13
 Procalcitonin (PCT), the prototype of a hormokine 
mediator, is released from all cell types throughout the 
body by microbial infections and is regarded as a reliable 
marker of sepsis.14, 15 Serum PCT levels have also been 
shown to be higher in cirrhotic patients with bacterial 
infection than in those without infection.16–20 However, 
no previous reports have evaluated PCT as a biomarker 
of ALF. This study aimed to evaluate the clinical value 
of serum PCT levels in patients with ALF.
SUBJECTS AND METHODS
Subjects
Between January 2001 and June 2015, a total of 85 con-
secutive hospitalized patients with acute hepatitis in the 
Department of Gastroenterology, Tottori Univeristy Hos-
pital in Yonago were retrospectively evaluated.  In this 
study, we defined acute hepatitis as ALT of more than 1.5 
times the upper normal limit (using 19IU/L for female 
and 30IU/L for male) without underlying chronic liver 
disease.21, 22 Chronic liver disease including cirrhosis 
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was diagnosed according to clinical, biochemical, and/
or imaging findings. Patients with underlying chronic 
liver disease, a history of alcoholism (ethanol consump-
tion more than 40 g/day and longer than 25 years), and 
drug-induced liver injury (DILI) were excluded from the 
study. All patients whose serum samples within 3 days 
after admission were unavailable were excluded from 
the study. A total of 44 patients (19 men and 25 women; 
median age, 40 years; range, 20–79 years) were enrolled. 
Definitions and examined items 
In Japan, ALF is defined as percent PT < 40% regard-
less of hepatic encephalopathy (HE), and it is divided 
into “ALF without HE” and “ALF with HE”.23 In this 
study, all the HE were diagnosed after admission. All 
the patients underwent blood biochemical examinations 
including Cre, total and direct bilirubin, aspartate ami-
notransferase (AST), alanine aminotransferase (ALT), 
alkaline phosphatase (ALP), gamma-glutamyl transpep-
tidase (GGT), alpha-fetoprotein (AFP), PT, and C-re-
active protein (CRP) within 24 h after hospitalization. 
All the patients were also tested for immunoglobulin M 
(IgM) and G (IgG) antibody against hepatitis A virus 
(HAV), hepatitis B surface antigen (HBsAg), hepatitis 
B envelop antigen (HBeAg), IgM antibody to hepatitis 
core antigen (IgM anti-HBc), hepatitis B viral (HBV) 
DNA, hepatitis C virus (HCV) antibody, HCV-RNA, 
and immunoglobulin A (IgA) antibodies to hepatitis E 
virus (HEV) using routine commercially available en-
zyme immune assays. IgM and IgG antibodies against 
Epstein-Barr virus (EBV), herpes simplex virus, cyto-
megalovirus (CMV) were assayed. In all the patients, 
systemic and focal bacterial infection was checked by 
2 sets of blood culture, urine test, ultrasonography and 
computed tomography. Serum PCT levels were mea-
sured with an Electro Chemi Luminescence Immuno 
Assay (BRAHMS PCT; Roche Diagnostics, Tokyo, 
Japan) in their saved sera obtained within 3 days after 
admission. 
Ethical Considerations
The study protocol was approved by the Institutional 
Review Board of our institute (No.1512A098) under the 
guidelines of the 1975 Declaration of Helsinki.
Statistical analysis
Data are expressed as median (range). Statistical anal-
yses for significant differences among the groups were 
performed using Mann-Whitney’s U test or the Krus-
kal-Wallis test. Correlations were calculated using Pear-
son’s product-moment correlation coefficient. Receiver 
operating characteristic (ROC) curve analysis was also 
used in order to determine the sensitivity and specificity 
of the serum PCT values for the detecting ALF in the 
study population. Univariate and multivariate analyses 
were performed using the multiple logistic regression 
analysis method. The cumulative survival rate was cal-
culated by the Kaplan-Meier method and significant dif-
ferences between the two groups were calculated using 
the log-rank test. All statistical analyses were performed 
using StatFlex (Windows ver. 6.0; Artech, Osaka, Ja-
pan). Statistical significance was set at P < 0.05.
RESULTS
Patient background
Baseline characteristics of the patients are presented 
in Table 1. Twenty-nine patients (66%) underwent liver 
biopsy. The etiology of acute hepatitis included HBV 
infection (n = 9), HCV infection (n = 3), CMV infection 
Table 1. Characteristics of 44 patients with acute  
hepatitis
Male/Female 19:25
Age (years) 40 (20–79)
Etiology
Viral infection 18 (40.9%)
   HBV 9
   HCV 3
   CMV 3
   EBV 3
Autoimmune hepatitis 7 (15.9%)
Others* 8 (18.2%)
Indeterminate 11 (25%)
Acute liver failure 16 (36.4%)
with HE 6 (13.6%)
without HE 10 (22.7%)
Laboratory values
AST　 1025 (47–20490) IU/L
ALT 884 (51–14510) IU/L
ALP 503 (122–2706) IU/L
GGT 186 (27–994) IU/L
Total bilirubin 3.85 (0.6–40.5) IU/L
D/T ratio 0.55 (0.11–0.73)
PT 59.4 (5–116) %
IgG 1603 (836–3690) mg/dL
Creatinine 0.7 (0.41–6.68) mg/dL
CRP 0.35 (0.04–20.11) mg/dL
AFP 4.9 (0.1–191.6) ng/mL
PCT 0.2 (0.03–2.66) ng/mL
*Other etiologies include Syphilis, Chlamydia, Mycoplasma, and 
diffuse large B cell lymphoma. Data are expressed as median 
(range).
AFP, alpha-fetoprotein; ALP, alkaline phosphatase; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; CRP, C-re-
active protein; CMV, cytomegalovirus; D/T ratio, direct and total 
bilirubin ratio; EBV, Epstein-Barr virus; GGT, gamma-glutamyl 
transpeptidase; HBV, hepatitis B virus; HCV, hepatitis C virus; 
HE, hepatic encephalopathy; Ig, immunoglobulin; PCT, procalci-
tonin; PT, percent prothrombin time. 
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Fig. 1. Differences in serum PCT levels in acute hepatitis. A: The serum PCT levels were signifi cantly higher in patients with ALF (n = 
16) than in those with non-ALF (n = 28) [0.25 (0.132.66) vs. 0.165 (0.03–1.08) ng/mL, P = 0.009]. **P < 0.01. B: relatively higher in ALF 
with HE (n = 6) than the others (n = 38) [0.52 (0.13–2.66) vs. 0.19 (0.03–1.73) ng/mL, P = 0.084]. ALF, acute liver failure; HE, hepatic en-
cephalopathy; PCT, procalcitonine.
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Fig. 2. The ROC curve of serum PCT levels for detecting ALF. 
The AUROC for serum PCT was 0.74 for detecting ALF in the 
cases of acute hepatitis on admission. ALF, acute liver failure; 
AUROC, area under the receiver operator characteristic; PCT, 
procalcitonine; ROC, receiver operating characteristic. 
Fig. 3. Cumulative survival rate with a PCT cut-off level of 0.5 ng/
mL. The cumulative survival rate was signifi cantly lower in the 
patients with PCT ≥ 0.5 ng/mL (P = 0.031). *P < 0.05. PCT, pro-
calcitonine.
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Table 3. Comparison of background between patients with low PCT and high PCT levels
PCT (ng/mL) P value
< 0.5 (n = 36) ≥ 0.5 (n = 8)
Gender (male:female) 16:20 3:5 0.720
Age (year) 38 (20–79) 48 (22–71) 0.692
Etiology (viral:non-viral) 16:20 2:6 0.312
Hepatic encephalopathy (yes:no) 33:3 4:4 0.004
AST (IU/L) 1030 (47–24090) 929 (254–15604) 0.503
ALT (IU/L) 985 (51–9598) 676 (217–14510) 0.715
ALP (IU/L) 521 (122–2706) 466 (275–617) 0.196
GGT (IU/L) 189 (38–994) 94 (27–266) 0.037
Total bilirubin (mg/dL) 3.05 (0.6–29.7) 7.15 (0.9–40.5) 0.385
D/T ratio 0.57 (0.11–0.73) 0.58 (0.27–0.71) 0.673
PT (%) 69 (12–116) 28 (5–24) 0.011
Creatinine (mg/dL) 0.69 (0.41–2.23) 0.74 (0.51–6.68) 0.308
CRP (mg/dL) 0.88 (0.04–20.11) 2.6 (0.23–14.66) 0.139
AFP (ng/dL) 4.9 (0.1–83.4) 6.15 (0.7–191.6) 0.585
Data are expressed as median (range). AFP, alpha-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; CRP, C-reactive protein; D/T ratio, direct and total bilirubin ratio; GGT, gamma-glutamyl transpeptidase; PCT, procal-
citonin; PT, percent prothrombin activity. 
Table 2. Correlations between serum PCT levels and  
clinical/biochemical parameters
Patients (n = 44) r (95% CI) P value
Age (year) 0.1711 (–0.133–0.445) 0.267
AST 0.171 (–0.133–0.445) 0.268
ALT 0.157 (–0.146–0.434) 0.307
ALP –0.130 (–0.411–0.173) 0.399
GGT –0.161 (–0.437–0.143) 0.297
Total bilirubin 0.454 (  0.182–0.663) 0.002
Direct bilirubin 0.541 (  0.288–0.724) < 0.001
D/T ratio 0.225 (–0.081–0.492) 0.146
PT –0.3930 (–0.618–0.109) 0.008
IgG –0.1164 (–0.406–0.194)  0.463
Creatinine 0.8078 (  0.672–0.891) < 0.001
CRP 0.2528 (–0.051–0.514) 0.102
AFP 0.1936 (–0.160–0.503) 0.280
AFP, alpha-fetoprotein; ALP, alkaline phosphatase; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; CI, confi-
dence interval; CRP, C-reactive protein; D/T ratio, direct and total 
bilirubin ratio; GGT, gamma-glutamyl transpeptidase; Ig, immu-
noglobulin; PCT, procalcitonin; PT, percent prothrombin activity.
(n = 3), EBV infection (n = 3), autoimmune hepatitis (n = 
7), other etiology (n = 8) and indeterminate (n = 11). Ten 
patients had ALF without HE and six patients had ALF 
with HE. Four patients of “ALF with HE” died (one by 
suicide) during the study period. One patient with HE 
was not ALF since the HE was considered to be induced 
by a disorder in the urea cycle. The main etiology of 
ALF was HBV (43.8%). None of the patients were diag-
nosed with a systemic or focal bacterial infection. There 
were no cases of spontaneous bacterial peritonitis (SBP). 
Six patients received artificial liver support using he-
modialysis, and 10 patients underwent plasma exchange 
in addition to conventional supportive treatment. Sub-
sequently, three patients died of hepatic failure and one 
patient unfortunately committed suicide after recovery. 
No patient received liver transplantation because of no 
available donor organs. There were no missing data or 
outliers in obtained serum PCT. 
Analysis of serum procalcitonin levels
Serum PCT levels were significantly higher in the pa-
tients with ALF (n = 16) than in those with non-ALF (n 
= 28) [0.25 (0.13–2.66) vs. 0.165 (0.03–1.08) ng/mL, P = 
0.00967] (Fig. 1A), and relatively higher in ALF with HE 
than the others [0.52 (0.13–2.66) vs. 0.19 (0.03–1.73) ng/
mL, P = 0.084] (Fig. 1B). Creatinine, total bilirubin, and 
direct bilirubin were positively and PT was negatively 
correlated with PCT. (Table 2). The area under the ROC 
(AUROC) was 0.74 for detecting ALF on admission 
(Fig. 2). The cutoff value of 0.5 ng/mL for PCT showed 
a low sensitivity (37.5%) and a higher specificity (96.5%) 
for detecting ALF on admission. The positive predictive 
value (PPV) and negative predictive value (NPV) were 
85.7% and 72.9%, respectively. We compared the clini-
cal parameters between patients with low PCT (< 0.5 ng/
mL) and those with high PCT (≥ 0.5 ng/mL). The prev-
alence of HE was significantly higher in the high PCT 
group than in the low PCT group. On the other hand, 
the serum GGT and PT levels were significantly lower 
in the high PCT group than in the low PCT group (Table 
3). It is not surprising that the number of patients com-
plicated with HE was greater in ALF group. The levels 
of serum AST [589 (47–3016) vs. 1925 (154–24090), P = 
0.0011], ALT [639.5 (51–3612) vs. 2782 (141–14510), P = 
0.0004], total bilirubin [1.8 (4.3–5.8) vs. 10 (1.4–40.5), P 
= 0.0002], D/T ratio [0.39 (0.11–0.69) vs. 0.65 (0.3–0.73), 
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Table 4. Differences between non-ALF and ALF 
Non-ALF (n = 28) ALF (n = 16) P value
Gender (male:female) 12:16 7:9 0.956
Age (year) 39 (20–79) 40 (22–71) 0.877
Etiology (viral:non-viral) 11:17 7:9 1.000
Hepatic encephalopathy (yes:no) 1:27 5:11 0.010
AST      (IU/L) 589 (47–3016) 1925 (154–24090) 0.001
ALT        (IU/L) 639.5 (51–3612) 2782 (141–14510) < 0.001
ALP        (IU/L) 546 (122–2706) 465.5 (275–617) 0.089
GGT         (IU/L) 189 (38–994) 162.5 (27–613) 0.193
Total bilirubin (mg/dL) 1.8 (4.3–5.8) 10 (1.4–40.5) < 0.001
D/T ratio 0.39 (0.11–0.69) 0.65 (0.3–0.73) 0.013
Creatinine   (mg/dL) 0.66 (0.41–1.17) 0.82 (0.41–6.68) 0.022
CRP        (mg/dL) 0.89 (0.06–20.11) 1.3 (0.04–5.93) 0.450
AFP (ng/dL) 28.5 ( 0.1–56.7) 6.15 (0.7–191.6) 0.290
PCT         (ng/dL) 0.165 (0.03–1.08) 0.22 (0.13–2.66) 0.008
Data are expressed as median (range).  ALF, acute liver failure; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspar-
tate aminotransferase; GGT, gamma-glutamyl transpeptidase; D/T ratio, direct and total bilirubin ratio; CRP, C-reactive protein; AFP, 
alpha-fetoprotein; PCT, procalcitonin. 
Table 5. Multivariate analysis for detecting ALF on admission
Odds ratio 95% CI P value
PCT (ng/dL) 52.15 (1.08–2525.65) 0.046
AST >1000 (IU/L) 1.50 (0.09–24.21) 0.775
ALT >1000 (IU/L) 5.97 (0.35–101.39) 0.217
Total bilirubin (mg/dL) 1.08 (0.92–1.27) 0.363
D/T ratio 6.37 (0.01–4256.02) 0.577
Creatinine (mg/dL) 27.43 (0.41–1855.89) 0.124
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; D/T ratio, direct and total bilirubin ratio; PCT, 
procalcitonin.
P = 0.0132], Cre [0.66 (0.41–1.17) vs. 0.82 (0.41–6.68), 
P = 0.022], and serum PCT [0.165 (0.03–1.08) vs. 0.22 
(0.13–2.66), P = 0.0082], showed significant differences 
between non-ALF and ALF patients (Table 4). Multiple 
logistic regression analysis revealed PCT to be an inde-
pendent factor for detecting ALF on admission (Table 
5). In this multiple regression analysis, HE was excluded 
because it was not the factor on admission. The cumula-
tive survival rate was significantly lower in patients with 
PCT ≥ 0.5 ng/mL than in those with PCT < 0.5 ng/mL (P 
= 0.0314) (Fig. 3). However, multivariate analysis did not 
demonstrate PCT as an independent prognostic factor.
DISCUSSION
This study provided two novel findings. First, serum 
PCT levels in patients with ALF were significantly high-
er than those in non-ALF patients. Second, this is the 
first report to demonstrate that the serum PCT level was 
independently associated with ALF.
 To our knowledge, only two reports have thus far 
evaluated serum PCT in acute hepatitis. Elefsiniotis et 
al.24 evaluated serum PCT levels in a small sample (n = 
13) of patients with acute icteric viral hepatitis (including 
4 patients with acute exacerbation of chronic viral hepa-
titis), and indicated no remarkable elevation (0.37 ± 0.22 
ng/mL) as compared with a group of decompensated 
cirrhosis with culture-proven bacterial infection (9.8 ± 
16.8 ng/mL). Another report was a case presentation of 
acute Q-fever granulomatous hepatitis.25 The hepatitis 
was induced by bacterial (Coxiella brunetii) infection 
and treated by antibiotics; the authors concluded that the 
serum PCT level was useful for monitoring the treatment 
of bacterial hepatitis. In both these reports, serum PCT 
levels were not evaluated in ALF cases. On the other 
hand, some reports have evaluated serum PCT levels in 
cirrhotic patients with chronic liver failure.16–20 In these 
reports, the serum PCT levels were mainly evaluated for 
detecting bacterial infection in cirrhosis, such as SBP in-
duced by bacterial translocation (BT). No study has thus 
far evaluated the clinical significance of serum PCT in 
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ALF. The present study showed that serum PCT levels 
in ALF patients were significantly higher than those in 
non-ALF patients. 
 There were some patients with elevated CRP, how-
ever, none of the patients was diagnosed with focal and 
systemic bacterial infection. There are only small num-
ber of reports mentioned about the relationship between 
hepatitis and CRP. Wigmore SJ et al.26 indicated that the 
serum CRP concentration in patients with fulminant he-
patic failure on the day of admission was high [6 (2.2–8.6) 
mg/dL], and they thought it may have been stimulated 
by pro-inflammatory cytokines. Atono Y et al.27 also 
reported that CRP was markedly increased in the acute 
phase of acute hepatitis type A (1.34 ± 2.18mg/dL) and B 
(0.88 ± 0.78mg/dL). According to these reports, to some 
extent, serum CRP levels might be affected by acute 
hepatitis. Considering our four patients with higher CRP 
(≥ 5), their final diagnoses were autoimmune hepatitis 
(AIH) (CRP 5.93mg/dL), diffuse large B cell lymphoma 
(DLBCL) (CRP 7.06mg/dL) and two unknowns (CRP 
14.7 and 20.1mg/dL). In the AIH case, the CRP gradu-
ally decreased from 5.93 to 1.83 mg/dL at two weeks of 
admission, and in DLBCL case, it also decreased gradu-
ally from 7.06 to 0.4 mg/dL at three weeks of admission. 
Probably, these CRP levels might be affected by these 
backgrounds. On the other hand, one of the two pa-
tients with unknown cause was administered antibiotics 
empirically, and the CRP level decreased from 14.7 to 
2.4mg/dL at fourth day of admission. The other patient 
with unknown cause was not administered any antibi-
otics, and the CRP decreased from 20.1 to 2.8 mg/dL at 
fourth day of admission. These two cases demonstrated 
a similar clinical course in CRP levels regardless of an-
tibiotics. There were no remarkable inflammatory back-
grounds such as autoimmune diseases in these cases. 
The dynamics of CRP in acute hepatitis with unknown 
causes has still been remained unclear.
 In the absence of bacterial infection, serum PCT lev-
els were also reported to be elevated in cases of surgery, 
trauma, cardiogenic shock, severe pancreatitis, severe 
renal and liver dysfunction (Child-Pugh C), and multiple 
organ failure.28 
 In this study, we found the strong positive correla-
tion between PCT and Cre. PCT has been reported to 
predict the acute kidney injury complicated with infec-
tion or acute pancreatitis.29, 30 The reason may be due to 
the plasma disappearance rate prolongation of PCT in 
renal dysfunction.31 Renal dysfunction is also reported 
frequently complicated with ALF.32 However, no previ-
ous reports demonstrated the relation between PCT and 
renal dysfunction in ALF. 
 Although the mechanism for the PCT elevation in 
ALF remains unknown, subsequent endotoxemia and 
systemic inflammation may also play important roles in 
PCT elevation. BT may be involved in high serum PCT 
levels in ALF.33 Further study with a larger number of 
patients is needed to clarify these observations. 
 We selected serum PCT level of 0.5 ng/mL as an 
optimal cut-off level for detecting ALF. This cut-off val-
ue showed high specificity but low sensitivity. Although 
the cut-off value of 0.5 ng/mL is used for diagnosing 
sepsis,28 an optimal cut-off value for ALF needs to be 
validated by further studies.
 This is the first report to evaluate PCT in ALF. 
However, this study is a retrospective study with a rel-
atively small number of cases. Therefore, we could not 
demonstrate PCT as a distinct predictive and prognos-
tic biomarker for ALF with HE. To evaluate PCT as a 
predictive and prognostic marker for ALF with HE, our 
findings should be validated in a larger sample size with 
a prospective cohort. 
 In conclusion, serum PCT level was significantly 
higher in patients with ALF following acute hepatitis. 
PCT is expected to be an early predictive biomarker in 
acute hepatitis.
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